higher order crossover methodology [General Sta­tis­tics]

posted by Relaxation  – Germany, 2020-06-30 16:10 (952 d 00:18 ago) – Posting: # 21618
Views: 5,777

Dear Sveta.

Nothing to add to the answer already given.
I just want to ask, whether you may want to give some more background information on the situation.
Because I really was not able to think of a scenario, where considering only a part of the population based on the sequences could provide a benefit (unless its a sneaky two-stage, but then as said: nothing to add to the answer given).
Likely just a case of limited imaginative power on my side :ponder:.

Best regards,

Steven.

Complete thread:

UA Flag
Activity
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
21 visitors (0 registered, 21 guests [including 8 identified bots]).
Forum time: 15:29 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5